INSIGHTS ON SOLID DOSE MANUFACTURING

• Seizing Market Share Pre-Patent Expiry: The Evolution Of A CDMO Partnership In Navigating A Paragraph IV ANDA Submission

  The dynamic pharmaceutical landscape demands agility and strategic foresight. Explore how leveraging a key partnership helped to overcome a looming patent expiry for a second-generation acne medication.

• NanoImprove The Performance Of Your Formulations

  Learn how Nanoforming can help improve the performance of your molecule by increasing drug loads, improving bioavailability, enhancing drug delivery profiles, and supporting product differentiation.

• How High Drug Load Nanocrystalline Tablets Lower Pill Burden

  We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.

• Developing And Manufacturing Minitablets To Extend Drug Lifecycle

  Pharmaceutical companies should leverage oral minitablets to extend drug lifecycles, optimize dosing, and improve patient-centric solutions while overcoming manufacturing challenges.

• Taste-Masked Dosage Forms For Pediatric Oral Delivery: An Industrial Perspective

  7/18/2024

  Leveraging strategies and technologies for pediatric patient compliance for taste masking and controlled release in pharmaceutical products, enables flexibility in dosage and format options.

• FastLok™ Die Table Surface Overview

  10/8/2025

  Learn about a toolless, removable surface that allows for rapid, on-turret plate replacement in minutes, not weeks, significantly improving operational efficiency.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

• Technologies And Patient-Centric Solutions

  7/18/2024

  Our innovative technology platforms, including Taste Masked Microcaps® and Optimµm®, address issues like taste masking, swallowability, and controlled release to improve patients' quality of life.

• Advancing Patient-Centric Drug Delivery For Neurodegenerative Disease With Orally Dissolving Tablets

  1/27/2025

  Pharmaceutical companies must prioritize patient-centric dosage forms to address challenges like dysphagia, enhance medication compliance, and improve therapeutic outcomes.